Company intelligence / Profile preview

Kovina Therapeutics

Indianapolis, Indiana, United Stateskovina.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Kovina Therapeutics is developing first-in-class small molecule antiviral therapies that selectively target and inactivate a key HPV protein. Their approach aims to kill infected cells, providing a non-surgical treatment option for both pre-cancerous lesions and established cancers caused by HPV. The company is currently at the preclinical stage with no human clinical results reported yet.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeAntiviral therapy
Industry: Biotech

Drug pipeline

2 assets

Kovina HPV E6 inhibitor

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Indiana University (IU): scientific research collaboration; IP licensed from IU

Beyond the preview

Go deeper on Kovina Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kovina Therapeutics.

Explore the full profile